Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment
| العنوان: | Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment |
|---|---|
| المؤلفون: | Yasuki Uchida, Masaki Fujita, Akira Nakao, Noriya Hiraoka, Tomoyuki Araya, Masaya Akai, Takako Mouri, Tamotsu Ishizuka, Tadaaki Yamada, Yasuhiro Goto, Keita Nakatomi, Takayuki Takeda, Yoshiko Kaneko, Chikara Sakaguchi, Hidetaka Uramoto, Toshihide Yokoyama, Minoru Fukuda, Seiji Nagashima, Osamu Hiranuma, Hisao Imai, Yusuke Chihara, Koichi Takayama, Nobuyo Tamiya, Tadashi Mio, Junji Uchino, Noboru Hattori, Kiyoaki Uryu, Kenichi Yoshimura, Masayuki Kawasaki |
| المصدر: | Journal of Clinical Medicine Volume 9 Issue 6 Journal of Clinical Medicine, Vol 9, Iss 1762, p 1762 (2020) |
| بيانات النشر: | MDPI AG, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | medicine.medical_specialty, Anemia, lcsh:Medicine, Neutropenia, T790M, Gastroenterology, Article, 03 medical and health sciences, 0302 clinical medicine, EGFR-TKI, Internal medicine, Medicine, Osimertinib, 030212 general & internal medicine, Hypoalbuminemia, Adverse effect, Lung cancer, non-small cell lung cancer, Pneumonitis, business.industry, lcsh:R, General Medicine, medicine.disease, respiratory tract diseases, osimertinib, 030220 oncology & carcinogenesis, business |
| الوصف: | Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used for treating EGFR-mutated lung cancer, and osimertinib is effective in cases that acquired T790M mutations after treatment with the first- and second-generation EGFR-TKIs. However, no study has evaluated its safety and efficacy in older patients. This phase II trial (jRCTs071180002) evaluated osimertinib in T790M mutation-positive Japanese patients who were &ge 75 years old and had experienced relapse or progression after previous EGFR-TKI treatment. Our previous report that enrolled 36 patients showed the overall response rate (58.3%) and disease control rate (97.2%), while this report describes the results for the progression-free survival (PFS), overall survival (OS), and safety analyses. The median PFS was 11.9 months (95% confidence interval (CI): 7.9&ndash 17.5), and the median OS was 22.0 months (95% CI: 16.0 months&ndash not reached). The most frequent adverse events were anemia/hypoalbuminemia (27 patients, 75.0%), thrombocytopenia (21 patients, 58.3%), and paronychia/anorexia/diarrhea/neutropenia (15 patients, 41.7%). Pneumonitis was observed in four patients (11.1%), including two patients (5.6%) with Grade 3&ndash 4 pneumonitis. These results suggest that osimertinib was relatively safe and effective for non-small cell lung cancer that acquired T790M mutations after previous EGFR-TKI treatment, even among patients who were &ge 75 years old. |
| وصف الملف: | application/pdf |
| تدمد: | 2077-0383 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35328b22e5d7984f70b93ce61df36f09Test https://doi.org/10.3390/jcm9061762Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....35328b22e5d7984f70b93ce61df36f09 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20770383 |
|---|